FOXA1 in prostate cancer
作者机构：Department of UrologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjing 210029China Department of Clinical MedicineSuzhou Vocational Health CollegeSuzhou 215009China
出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)
年 卷 期：2023年第25卷第3期
页 面：287-295页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：This work was supported by the National Natural Science Foundation of China(82002718) the Jiangsu Natural Science Foundation(BK20191077)
主 题：androgen receptor forkhead box protein A1 mutation prostate cancer
摘 要：Most prostate cancers initially respond to androgen deprivation therapy(ADT).With the long-term application of ADT,localized prostate cancer will progress to castration-resistant prostate cancer(CRPC),metastatic CRPC(mCRPC),and neuroendocrine prostate cancer(NEPC),and the transcriptional network *** box protein A1(FOXA1)may play a key role in this process through multiple *** better understand the role of FOXA1 in prostate cancer,we review the interplay among FOXA1-targeted genes,modulators of FOXA1,and FOXA1 with a particular emphasis on androgen receptor(AR)***,we discuss the distinct role of FOXA1 mutations in prostate cancer and clinical significance of *** summarize possible regulation pathways of FOXA1 in different stages of prostate *** focus on links between FOXA1 and AR,which may play different roles in various types of prostate ***,we discuss FOXA1 mutation and its clinical significance in prostate ***1 regulates the development of prostate cancer through various pathways,and it could be a biomarker for mCRPC and *** efforts need to focus on mechanisms underlying mutation of FOXA1 in advanced prostate *** believe that FOXA1 would be a prognostic marker and therapeutic target in prostate cancer.
维普期刊数据库